5 n n hexamethylene amiloride hma

A table containing all employed antibodies as well as their cellular target, supplier and catalogue number is provided as Supplementary Table S2.
Cariporide was a gift from Sanofi-Aventis and 5-(N-ethyl-N-isopropyl) amiloride (EIPA) (#E3111) was from Thermo-Fisher. β-actin antibody (#A5441), tamoxifen (#T5648), cisplatin (#P4394), 5-fluorouracil (5-FU) (#F6627), 5-(N,N-Dimethyl) amiloride (DMA) (#A4562), 5-(N,N-Hexamethylene) amiloride (HMA) (#A9561) and amiloride (#A7410) were from Sigma-Aldrich, and doxorubicin (#120629) and eniporide (#HY-106150B) from Abcam and MedChemExpress, respectively. Akt (Akti, #124018) and MEK (U0126, #662005) inhibitors were from Calbiochem. Horseradish Peroxidase (HRP)-conjugated anti-mouse- (#P0447) and anti-rabbit (#P0448) antibodies were from Dako, and Alexa Fluor anti-mouse (#A11019) and anti-rabbit (#A11070) fluorophore-conjugated secondary antibodies were from Invitrogen.

Rho-associated protein kinase (ROCK) inhibitor Y-27632 and epidermal growth factor (EGF) were obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan), and a p38 MAP kinase inhibitor SB203580 was obtained from Cayman Chemical (Ann Arbor, MI, USA). SB431543 (SB4), originally thought to block the negative effect of transforming growth factor-β on cultures, Dulbecco’s modified Eagle’s medium, high glucose (DMEM-HG), and fetal bovine serum were obtained from Thermo Fisher Scientific (Waltham, MA, USA), and plastic culture plates were obtained from Corning (Corning, Inc., Corning, NY, USA). Ammonium chloride (NH₄Cl), an inhibitor of NHE1; 5-(N,N-hexamethylene) amiloride (HMA), an inhibitor of NBCe1; S0859, an inhibitor of monocarboxylate transporters 1 and 4 (MCT1, 4); and syrosingopine were obtained from Sigma-Aldrich, Inc. (St. Louis, MO, USA). Unless otherwise stated, all other chemicals were obtained from Sigma-Aldrich, Inc. (St. Louis, MO, USA).